First immunotherapy combination of ipilimumab plus nivolumab available to patients in England
We are very pleased to learn that the ipilimumab plus [...]
We are very pleased to learn that the ipilimumab plus [...]
New 30-month survival data from the CheckMate 214 study were [...]
Further survival data has been released from the phase 3 [...]
The following review of the literature for first-line treatment of [...]
The European Commission has approved the nivolumab plus ipilimumab combination [...]
Scientists at the Dana-Farber Cancer Institute in Boston, USA, are [...]
A recent analysis of data from the phase 3 Checkmate-214 [...]
We have just learnt the news that the Committee for Medicinal Products [...]
Analysis of the phase 3 CheckMate-214 study has shown that [...]
Immune-related adverse events (irAEs) are side effects that can develop [...]